Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
Paradigm, the latest startup focused on providing more patient diversity in clinical trials, launched with $203 million in series A funding.
NEW YORK, Oct. 4, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company), a late- stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to announce that the primary endpoint has been met and additionally significant improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores were demonstrated for injectable iPPS in the PARA_OA_008 phase 2 clinical trial.
Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company) a clinical stage biopharmaceutical company focussed on repurposing existing...
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has activated the first UK site in a Phase 3 study assessing the effect of Zilosul® on osteoarthritis, beginning the screening and recruitment process after receiving regulatory and ethics approval from the UK.
Paradigm Biopharmaceuticals (ASX: PAR) a clinical stage biopharmaceutical company focused on repurposing existing molecules for new indications with...
MELBOURNE, Australia, March 17, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals (ASX: PAR) a global biopharmaceutical company driven to improve patients' lives through repurposing existing drugs and pioneering new solutions for unmet medical needs, is announcing today the official launch of their U.S. clinical trial program with an estimated 56 planned clinical trial locations nationwide for the conduct of the pivotal phase 3 trial to support registration of Pentosan Polysulfate Sodium (PPS) for osteoarthritis (OA) of the knee.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has released positive top-line results of the actions of pentosan polysulfate sodium (PPS) in the influenza model of acute respiratory distress syndrome (ARDS).